Drug · Monoclonal Antibody
Elranatamab
CI-DRUG-00000761Explore in graph →CHEMBL4297809 Approved
Regulatory
Approvals (5)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| CA Health Canada | — | Marketed in Canada as ELREXFIO (DIN 02543559) under ATC L01FX32 ELRANATAMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Jan 23, 2024 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as ELREXFIO (DIN 02543567) under ATC L01FX32 ELRANATAMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Jan 23, 2024 | health-canada-dpd |
| EU EMA | Multiple Myeloma | Elrexfio is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.conditional | approved | Dec 7, 2023 |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 20 hours agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 4 | 35 | 26 | 6 | 38 | 5 | CA, EU, US | Aug 14, 2023 | Aug 9, 2019 |
| Non-Hodgkin Lymphoma | Approved | Phase 4 | 35 | 26 | 6 | 38 | 2 | EU, US | Aug 14, 2023 | Aug 9, 2019 |
| Multiple Myeloma | Approved | Phase 4 | 33 | 25 | 5 | 36 | 2 | EU, US | Aug 14, 2023 | Aug 9, 2019 |
| Leukemia | Phase2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — |
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (47)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06421675 | Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma(EMBRACE) | recruiting | Phase 2 | 40 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05623020 | A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant |